StonvexLoading…
StonvexStonvexStonvexCore line items from MCY's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $29.60M | $25.20M | $20.80M | $18.20M |
Operating Income | $663.65M | $574.88M | $99.43M | $-670.72M |
Net Income | $541.09M | $467.95M | $96.34M | $-512.67M |
EPS (Diluted) | $9.77 | $8.45 | $1.74 | $-9.26 |
Total Assets | $9.56B | $8.31B | $7.10B | $6.51B |
Total Liabilities | $7.14B | $6.36B | $5.56B | $4.99B |
Cash & Equivalents | $1.32B | $720.26M | $550.90M | $289.78M |
Free Cash Flow OCF − CapEx | $1.03B | $990.98M | $416.19M | $317.08M |
Shares Outstanding | 55.39M | 55.39M | 55.37M | 55.37M |